HER2-positive breast cancer, characterized by overexpression of the human epidermal growth factor receptor 2, constitutes about 20%–25% of all breast cancer cases and is associated with a more aggressive disease course and poorer prognosis (Slamon et al., 1989; Harbeck et al., 2019). Here, ERBB2 is linked to breast cancer.